ALX Oncology (NASDAQ:ALXO) Stock Price Down 4.8%

ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded down 4.8% during mid-day trading on Monday . The company traded as low as $14.85 and last traded at $14.85. 92,072 shares changed hands during trading, a decline of 79% from the average session volume of 430,712 shares. The stock had previously closed at $15.60.

Analyst Ratings Changes

A number of research analysts have weighed in on ALXO shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of ALX Oncology in a research note on Wednesday, April 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.83.

ALX Oncology Price Performance

The firm has a fifty day simple moving average of $13.60 and a 200-day simple moving average of $12.15. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, sell-side analysts forecast that ALX Oncology Holdings Inc. will post -3.33 EPS for the current fiscal year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the transaction, the insider now directly owns 628,359 shares in the company, valued at approximately $7,006,202.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now directly owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jason Lettmann acquired 4,400 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Insiders own 50.30% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its position in ALX Oncology by 445.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after acquiring an additional 4,706 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 3rd quarter worth approximately $168,000. SG Americas Securities LLC raised its holdings in shares of ALX Oncology by 201.4% in the 4th quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock worth $452,000 after purchasing an additional 20,279 shares during the period. Barclays PLC lifted its stake in ALX Oncology by 57.1% in the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after purchasing an additional 9,796 shares during the last quarter. Finally, Forefront Analytics LLC bought a new position in ALX Oncology during the third quarter valued at $66,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.